Meanwhile, hemophilia A drug Altuviiio reached nearly a quarter of a billion euros in sales in the fourth quarter, with Sanofi crediting that growth to an increasing number of patients switching ...

Among Sanofi’s rare disease drugs, its new rare blood disorder drug, Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of €230 million in the fourth ...

The Sanofi Global Health Unit plays an important ... And the second question, a very short one, given the current dynamics with ALTUVIIIO, is that one your next blockbuster and no later than ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Altuvoct (efanesoctocog alfa) to be used to ...

Sanofi (NASDAQ: SNY) Q4 2024 Earnings Call Jan 30, 2025, 9:00 a.m. ET Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. Contents: Prepared Remarks ...

Sanofi (NASDAQ:SNY) Q4 2024 Earnings Call Transcript ... In hemophilia, an increasing number of patients switched to ALTUVIIIO from both factor and non-factor therapies. We're seeing strong ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Sobi’s Sanofi-partnered efanesoctocog alfa has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA ...

Sanofi: Q4 sales growth of 10.3% ... 8% of total sales, led by ALTUVIIIO Dupixent sales up 16.0% to €3.5 billion Vaccines sales up 10.8% to €2.2 billion, driven by Beyfortus sales in Europe ...

Sanofi’s sales rose 10% on a constant currency rate (“CER”) basis, while earnings per share declined 11%. Higher sales of Dupixent and contributions from new products like Altuviiio and ...